Bora Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Bobby Sheng
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.8yrs |
| CEO ownership | 6.4% |
| Management average tenure | 7.7yrs |
| Board average tenure | 9yrs |
Recent management updates
Recent updates
Cautious Investors Not Rewarding Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Performance Completely
Mar 30
We Think Bora Pharmaceuticals (TWSE:6472) Can Stay On Top Of Its Debt
Jan 20Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem
Nov 21Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?
Oct 04Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects
Jul 18Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?
Jun 13Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Apr 10Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt
Apr 08Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality
Mar 14Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?
Apr 30Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?
Mar 17Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment
Feb 17
New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)
Jan 27Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt
Jan 19CEO
Bobby Sheng
10.8yrs
Tenure
Mr. Pao-Shi Sheng, also known as Bobby, serves as Chairman of the Board at Tanvex BioPharma, Inc. from March 27, 2025. He serves as Chairman of the Board at SunWay Biotech Co. LTD. since 2024.He Founder o...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | no data | no data | 6.36% NT$ 4.7b | |
| CFO of HQ & APAC | 12.3yrs | no data | no data | |
| Corporate Human Resource Director | 3.3yrs | no data | no data | |
| VP & Director | 12.1yrs | no data | 1.05% NT$ 774.5m | |
| Senior VP of Marketing and Sales - CDMO Business | no data | no data | no data | |
| CFO of North America | no data | no data | no data | |
| Senior Vice President of Taiwan Site Operations | 2.3yrs | no data | no data | |
| Deputy General Manager | no data | no data | 0.016% NT$ 11.6m | |
| Deputy General Manager | no data | no data | 0.098% NT$ 72.0m |
7.7yrs
Average Tenure
Experienced Management: 6472's management team is seasoned and experienced (7.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 10.8yrs | no data | 6.36% NT$ 4.7b | |
| VP & Director | 10.8yrs | no data | 1.05% NT$ 774.5m | |
| Independent Director | 7.9yrs | no data | 0.022% NT$ 16.4m | |
| Independent Director | 10.1yrs | no data | no data | |
| Director | 10.8yrs | no data | no data | |
| Director | 5.9yrs | no data | no data | |
| Independent Director | 7.9yrs | no data | no data | |
| Independent Director | 1.9yrs | no data | no data |
9.0yrs
Average Tenure
Experienced Board: 6472's board of directors are considered experienced (9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 10:19 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bora Pharmaceuticals Co., LTD. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| Hsuan Chen | KGI Securities Co. Ltd. |
| null null | KGI Securities Co. Ltd. |